Related Experiment Video
Updated: Jun 23, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Hypoxia targeting gene expression for breast cancer gene therapy
1Department of Bioengineering, College of Engineering, Hanyang University, 17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea. minhyung@hanyang.ac.kr
Abstract:
Gene therapy is a promising strategy to treat various inherited and acquired diseases. However, targeting gene expression to specific tissue is required to minimize side effects of gene therapy. Hypoxia is present in the microenvironment of solid tumors such as breast tumors. A hypoxic tumor targeting gene expression system has been developed for cancer gene therapy. In hypoxic tissues, hypoxia inducible factor (HIF)-1alpha is accumulated and stimulates transcription of the genes that have hypoxia response elements (HREs) in their promoters. Therefore, transcriptional regulation with a hypoxia inducible promoter is the most widely used strategy for hypoxic tumors targeting gene therapy. In breast cancer gene therapy, breast tumor specific promoters in combination with HREs have been used to induce gene expression in hypoxic breast tumors. Post-transcriptional regulation using an untranslated region (UTR) is also a useful strategy to increase gene expression in hypoxic tumor tissue. In addition, post-translational regulation with the oxygen-dependent degradation (ODD) domain is effective to eliminate therapeutic gene products and reduce side effects in normal tissue. In combination with the breast tumor specific promoters, hypoxic tumor targeting strategies will be useful for the development of a safe breast cancer gene therapy.
Insights
Developing targeted gene therapy for breast cancer is crucial. This study explores hypoxia-inducible gene expression systems to specifically target tumors, enhancing safety and efficacy in cancer gene therapy.
Area of Science:
- Biomedical Engineering
- Molecular Biology
- Oncology
Background:
- Gene therapy offers potential for treating diseases but requires precise tissue targeting to minimize side effects.
- Solid tumors, including breast tumors, often exhibit a hypoxic microenvironment.
- Hypoxia-inducible factor (HIF)-1alpha accumulation in hypoxic tissues drives gene transcription via hypoxia response elements (HREs).
Purpose of the Study:
- To develop and evaluate a gene expression system for targeting hypoxic breast tumors.
- To enhance the specificity and safety of gene therapy for breast cancer.
- To explore transcriptional, post-transcriptional, and post-translational regulatory strategies for hypoxia-targeted gene delivery.
Main Methods:
- Utilizing hypoxia-inducible promoters containing HREs to drive gene expression in hypoxic conditions.
- Employing breast tumor-specific promoters in conjunction with HREs for enhanced tumor targeting.
- Investigating the use of untranslated regions (UTRs) for post-transcriptional regulation.
- Incorporating the oxygen-dependent degradation (ODD) domain for post-translational regulation to control therapeutic gene product levels.
Main Results:
- Hypoxia-inducible promoters with HREs demonstrate potential for targeting gene expression in hypoxic tumors.
- Combining breast tumor-specific promoters with HREs enhances gene expression specifically within hypoxic breast tumors.
- Post-transcriptional and post-translational regulatory mechanisms can further refine gene expression and reduce off-target effects.
Conclusions:
- Transcriptional regulation via hypoxia-inducible promoters is a key strategy for targeting gene therapy to hypoxic tumors.
- Integrating breast tumor-specific promoters with HREs improves the precision of gene delivery in breast cancer.
- Combined regulatory strategies, including post-transcriptional and post-translational controls, are essential for developing safe and effective breast cancer gene therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Regulation of Angiogenesis and Blood Supply
01:23Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...